Lurie Cancer Center Support Grant Renewed

Publication
Article
OncologyONCOLOGY Vol 11 No 2
Volume 11
Issue 2

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Center of Northwestern University, announced that the Center has been awarded a 4-year competitive renewal of its Cancer Center Support Grant (CCSG) from the National

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Centerof Northwestern University, announced that the Center has been awardeda 4-year competitive renewal of its Cancer Center Support Grant (CCSG)from the National Cancer Institute. The grant award of $1.47 million peryear supports the cancer research infrastructure of the Lurie Cancer Center.

The Robert H. Lurie Cancer Center of Northwestern University, a NationalCancer Institute-designated clinical cancer center, is the focus of cancerresearch, education, and patient care at Northwestern University. The LurieCancer Center coordinates clinical research and cancer patient care programsat the teaching affiliates of the Northwestern University Medical School,and, through the Northwestern Healthcare Network, is associated with thefollowing hospitals in the Chicago area: Children's Memorial Medical Center,Evanston and Glenbrook Hospitals, Highland Park Hospital, Ingalls HealthSystem, Northwest Community Healthcare, Northwestern Memorial Hospital,Silver Cross Hospital, and Swedish Covenant Hospital.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content